Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

DIABETES

Another milestone in the evolution of GLP-1-based diabetes therapies

Nature Medicine volume 27, pages 952–953 (2021)Cite this article

Subjects

The first clinical study of an oral small-molecule GLP-1 receptor agonist suggests effective glycemic control and weight loss in patients with type 2 diabetes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Milestones in the clinical development of GLP-1-based glucose-lowering therapies.

References

  1. Parker, J. C. et al. J. Pept. Res. 52, 398–409 (1998).

    Article  CAS  Google Scholar 

  2. Saxena, A. R. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01391-w (2021).

    Article  Google Scholar 

  3. Sloop, K. W. et al. Diabetes 59, 3099–3107 (2010).

    Article  CAS  Google Scholar 

  4. Holst, J. J., Ørskov, C., Vagn-Nielsen, O. & Schwartz, T. W. FEBS Lett. 211, 169–174 (1987).

    Article  CAS  Google Scholar 

  5. Nauck, M. A. Metabolism 103, 154031 (2020).

    Article  CAS  Google Scholar 

  6. Nauck, M. A. & Meier, J. J. Eur. J. Endocrinol. 181, R211–R234 (2019).

    Article  CAS  Google Scholar 

  7. Nauck, M. A., Quast, D. R., Wefers, J. & Meier, J. J. Mol. Metab. 46, 101102 (2020).

    Article  Google Scholar 

  8. Davies, M. et al. J. Am. Med. Assoc. 318, 1460–1470 (2017).

    Article  CAS  Google Scholar 

  9. Gabery, S. et al. JCI Insight 5, e133429 (2020).

    Article  Google Scholar 

  10. Nauck, M. A., Kemmeries, G., Holst, J. J. & Meier, J. J. Diabetes 60, 1561–1565 (2011).

    Article  CAS  Google Scholar 

  11. Meier, J. J. et al. Diabetes Care 38, 1263–1273 (2015).

    Article  CAS  Google Scholar 

  12. Kawai, T. et al. Proc. Natl Acad. Sci. USA 117, 29959–29967 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetes Division, Katholisches Klinikum Bochum, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany

    Michael A. Nauck, Daniel R. Quast & Juris J. Meier

  2. Department of Internal Medicine, Augusta Kliniken, Bochum, Germany

    Juris J. Meier

Authors
  1. Michael A. Nauck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel R. Quast
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juris J. Meier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael A. Nauck.

Ethics declarations

Competing interests

M.A.N. has been member on advisory boards or has consulted with AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Menarini/Berlin Chemie, Merck, Sharp & Dohme, and NovoNordisk; has received grant support from AstraZeneca, Eli Lilly, Menarini/Berlin-Chemie, Merck, Sharp & Dohme, and NovoNordisk; and has served on the speakers’ bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly, Menarini/Berlin Chemie, Merck, Sharp & Dohme, and NovoNordisk. J.J.M. has received consulting and speaker honoraria from AstraZeneca, Eli Lilly, Merck, Sharp & Dohme, Novo Nordisk, Sanofi and Servier; and has received research support from Boehringer-Ingelheim, Eli Lilly &, Merck, Sharp & Dohme, Novo Nordisk, and Sanofi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nauck, M.A., Quast, D.R. & Meier, J.J. Another milestone in the evolution of GLP-1-based diabetes therapies. Nat Med 27, 952–953 (2021). https://doi.org/10.1038/s41591-021-01394-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01394-7

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing